NCT04398745Active, not recruitingPhase 1
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Nov 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- First submitted
- 25 Oct 2023
- Start date
- 23 Jul 2021
- Lead sponsor
- Glaxosmithkline Research & Development Limited
- Diseases
- Chronic kidney disease, Multiple myeloma
- EU CT number
- 2023-506063-34-00
- EudraCT number
- 2021-001237-40
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 9
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evangelismos S A Coordinator of this site? Confirm its status | Athens | Greece | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.